A consortium of venture capital firms and research institutions has formed the European Life Science Coalition to boost private and public investment into Europe’s biotech sector. The group—managing more than €24 billion—said it will address structural funding gaps that push startups to list in U.S. markets, and will coordinate capital mobilization and policy advocacy. Members framed the effort as critical to scaling local innovation, improving access to late‑stage capital and retaining companies through commercialization. The coalition’s actions may reshape funding flows and strategic partnerships across the continent.